Table 1. Open in new tab Patient...

Characteristics	All Patients	IDH Wildtype Subanalysis
Total number of patients	230		99
Sex
Male	138	60.0	65	65.7
Female	92	40.0	34	34.3
Age, y	Median: 51 (range, 14–83)		Median: 54 (range, 14–83)
KPS	Median: 80 (range 40–100)		Median: 80 (range 40–100)
≤80	161	70.0	66	66.7
>80	63	27.4	32	32.3
Unknown	6	2.6	1	1.0
Initial grade glioma
1–2	41	17.8	6	6.1
3	59	25.7	13	13.1
4	130	56.5	80	80.8
Initial radiotherapy dose
	Grade 1–2 Median: 54 Gy (range: 50.4–60 Gy)		Grade 1–2 Median: 54 Gy (range: 54–60 Gy)
	Grade 3–4 Median: 60 Gy (range: 45–75 Gy)		Grade 3–4 Median: 60 Gy (range: 50.4–75 Gy)
Concurrent TMZ with initial RT
Yes	193	83.9	91	91.9
No	28	12.2	5	5.1
Unknown	9	3.9	3	3.0
Recurrent grade glioma
3	56	24.4	N/A
4	174	75.7	N/A
Reirradiation at First or Subsequent Recurrence
First	134	58.2	64	64.7
Subsequent	95	41.3	35	35.4
Unknown	1	0.4	0	0
MGMT promoter
Nonmethylated	79	34.4	54	54.5
Methylated	77	33.5	38	38.4
Unknown	74	32.2	7	7.1
IDH
Wildtype	108	47.0	N/A	N/A
Mutated	57	24.8	N/A	N/A
Unknown	65	28.3	N/A	N/A

Characteristics

All Patients

IDH Wildtype Subanalysis

Number

Total number of patients

230

Sex

Male

138

60.0

65.7

Female

40.0

34.3

Age, y

Median: 51 (range, 14–83)

Median: 54 (range, 14–83)

KPS

Median: 80 (range 40–100)

≤80

161

70.0

66.7

>80

27.4

32.3

Unknown

2.6

1.0

Initial grade glioma

1–2

17.8

6.1

25.7

13.1

130

56.5

80.8

Initial radiotherapy dose

Grade 1–2
Median: 54 Gy (range: 50.4–60 Gy)

Grade 1–2
Median: 54 Gy (range: 54–60 Gy)

Grade 3–4 Median: 60 Gy (range: 45–75 Gy)

Grade 3–4 Median: 60 Gy (range: 50.4–75 Gy)

Concurrent TMZ with initial RT

Yes

193

83.9

91.9

12.2

5.1

Unknown

3.9

3.0

Recurrent grade glioma

24.4

N/A

174

75.7

N/A

Reirradiation at First or Subsequent Recurrence

First

134

58.2

64.7

Subsequent

41.3

35.4

Unknown

0.4

MGMT promoter

Nonmethylated

34.4

54.5

Methylated

33.5

38.4

Unknown

32.2

7.1

IDH

Wildtype

108

47.0

N/A

Mutated

24.8

N/A

Unknown

28.3

N/A

Characteristics	All Patients	IDH Wildtype Subanalysis
Total number of patients	230		99
Sex
Male	138	60.0	65	65.7
Female	92	40.0	34	34.3
Age, y	Median: 51 (range, 14–83)		Median: 54 (range, 14–83)
KPS	Median: 80 (range 40–100)		Median: 80 (range 40–100)
≤80	161	70.0	66	66.7
>80	63	27.4	32	32.3
Unknown	6	2.6	1	1.0
Initial grade glioma
1–2	41	17.8	6	6.1
3	59	25.7	13	13.1
4	130	56.5	80	80.8
Initial radiotherapy dose
	Grade 1–2 Median: 54 Gy (range: 50.4–60 Gy)		Grade 1–2 Median: 54 Gy (range: 54–60 Gy)
	Grade 3–4 Median: 60 Gy (range: 45–75 Gy)		Grade 3–4 Median: 60 Gy (range: 50.4–75 Gy)
Concurrent TMZ with initial RT
Yes	193	83.9	91	91.9
No	28	12.2	5	5.1
Unknown	9	3.9	3	3.0
Recurrent grade glioma
3	56	24.4	N/A
4	174	75.7	N/A
Reirradiation at First or Subsequent Recurrence
First	134	58.2	64	64.7
Subsequent	95	41.3	35	35.4
Unknown	1	0.4	0	0
MGMT promoter
Nonmethylated	79	34.4	54	54.5
Methylated	77	33.5	38	38.4
Unknown	74	32.2	7	7.1
IDH
Wildtype	108	47.0	N/A	N/A
Mutated	57	24.8	N/A	N/A
Unknown	65	28.3	N/A	N/A

Table 1.

Open in new tab

Patient Demographics

Characteristics	All Patients		IDH Wildtype Subanalysis
	Number	%	Number	%
Total number of patients	230		99
Sex
Male	138	60.0	65	65.7
Female	92	40.0	34	34.3
Age, y	Median: 51 (range, 14–83)		Median: 54 (range, 14–83)
KPS	Median: 80 (range 40–100)		Median: 80 (range 40–100)
≤80	161	70.0	66	66.7
>80	63	27.4	32	32.3
Unknown	6	2.6	1	1.0
Initial grade glioma
1–2	41	17.8	6	6.1
3	59	25.7	13	13.1
4	130	56.5	80	80.8
Initial radiotherapy dose
	Grade 1–2 Median: 54 Gy (range: 50.4–60 Gy)		Grade 1–2 Median: 54 Gy (range: 54–60 Gy)
	Grade 3–4 Median: 60 Gy (range: 45–75 Gy)		Grade 3–4 Median: 60 Gy (range: 50.4–75 Gy)
Concurrent TMZ with initial RT
Yes	193	83.9	91	91.9
No	28	12.2	5	5.1
Unknown	9	3.9	3	3.0
Recurrent grade glioma
3	56	24.4	N/A
4	174	75.7	N/A
Reirradiation at First or Subsequent Recurrence
First	134	58.2	64	64.7
Subsequent	95	41.3	35	35.4
Unknown	1	0.4	0	0
MGMT promoter
Nonmethylated	79	34.4	54	54.5
Methylated	77	33.5	38	38.4
Unknown	74	32.2	7	7.1
IDH
Wildtype	108	47.0	N/A	N/A
Mutated	57	24.8	N/A	N/A
Unknown	65	28.3	N/A	N/A

Characteristics	All Patients		IDH Wildtype Subanalysis
	Number	%	Number	%
Total number of patients	230		99
Sex
Male	138	60.0	65	65.7
Female	92	40.0	34	34.3
Age, y	Median: 51 (range, 14–83)		Median: 54 (range, 14–83)
KPS	Median: 80 (range 40–100)		Median: 80 (range 40–100)
≤80	161	70.0	66	66.7
>80	63	27.4	32	32.3
Unknown	6	2.6	1	1.0
Initial grade glioma
1–2	41	17.8	6	6.1
3	59	25.7	13	13.1
4	130	56.5	80	80.8
Initial radiotherapy dose
	Grade 1–2 Median: 54 Gy (range: 50.4–60 Gy)		Grade 1–2 Median: 54 Gy (range: 54–60 Gy)
	Grade 3–4 Median: 60 Gy (range: 45–75 Gy)		Grade 3–4 Median: 60 Gy (range: 50.4–75 Gy)
Concurrent TMZ with initial RT
Yes	193	83.9	91	91.9
No	28	12.2	5	5.1
Unknown	9	3.9	3	3.0
Recurrent grade glioma
3	56	24.4	N/A
4	174	75.7	N/A
Reirradiation at First or Subsequent Recurrence
First	134	58.2	64	64.7
Subsequent	95	41.3	35	35.4
Unknown	1	0.4	0	0
MGMT promoter
Nonmethylated	79	34.4	54	54.5
Methylated	77	33.5	38	38.4
Unknown	74	32.2	7	7.1
IDH
Wildtype	108	47.0	N/A	N/A
Mutated	57	24.8	N/A	N/A
Unknown	65	28.3	N/A	N/A

Abbreviations: IDH = Isocitrate dehydrogenase; y = year; KPS = Karnofsky performance status; Gy = gray; TMZ = temozolomide; RT = radiotherapy; N/A = not applicable; MGMT = O⁶-methylguanine DNA methyltransferase.

This Feature Is Available To Subscribers Only